CHOLANGIOCARCINOMA

This study tested an oral drug called infigratinib in 17 adults with advanced or spreading solid tumors that have certain FGFR gene mutations. The drug works by blocking overactive FGFR proteins that help cancer grow. The main goal was to see how many patients' tumors shrank or d…

This early-phase trial tested a new immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers that had minimal residual disease after standard treatment. The goal was to see if the treatment is safe and can reduce canc…

This early study tested a new drug called Cabotamig (ARB202) in 33 adults with advanced gastrointestinal cancers (like stomach, liver, or bowel cancer) that had stopped responding to standard treatments. The drug works by targeting a marker called CDH17 on cancer cells and helpin…

This study tested a drug called E7090 in 63 people with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion) and did not respond to standard chemotherapy. The goal was to see if the drug could shrink tumors. The treatment is not a cure, but aims to control …

This early-phase study tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, bone cancer, and brain tumors) that have a specific IDH1 gene mutation. The goal was to find the safest dose and see how the drug works in the body. Part…

This study looked at whether a Medtronic pump and Codman catheter could safely deliver chemotherapy directly to the liver in 35 people with colorectal cancer that spread to the liver or bile duct cancer. The main goal was to check safety, like liver side effects and need for sten…

This study tested a new drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block FGFR2, which can help slow or shrink tumors. The goal was to find the best dose and see how well it…

This study tested a combination of three treatments—chemotherapy directly into the liver (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—in 25 people with bile duct cancer that could not be removed by surgery. The goal was to see if the combination could sh…

This study tested a new PET imaging agent called [18F]FAPI-74 in 109 people with gastrointestinal cancers, including liver, bile duct, stomach, pancreas, and colorectal cancers. The goal was to see if the scan could accurately find cancer cells by targeting a protein called FAP. …

This study looked at whether a blood test can tell if bile duct cancer has spread to nearby lymph nodes before surgery. Researchers analyzed blood samples from 230 patients with intrahepatic cholangiocarcinoma. The goal is to help doctors choose the best treatment without needing…

This study looked at 200 people with suspected hilar cholangiocarcinoma, a rare bile duct cancer. Researchers compared two biopsy methods—one using an endoscope through the mouth and stomach, and another using a scope through the mouth into the bile duct—to see which was more acc…

This study looked at different methods for taking tissue samples from the bile duct during a procedure called ERCP. Researchers wanted to see which technique was safest and most accurate for diagnosing cancer or other diseases. Over 300 adults with narrowed bile ducts took part. …

This study collected information on the EchoTip AcuCore, a needle used to take tissue samples during an endoscopic ultrasound. The goal was to see how often the needle successfully gets a sample without needing a replacement. The study included 183 adults with various tumors or p…

This study looked at whether a new biomarker called 'mass response' can help predict how well cancer treatments will work. Researchers collected tumor cells from 72 adults with various cancers using fluid samples or biopsies. The goal was to see if this biomarker could guide ther…

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…